MedTrace Logo

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

NCT03501550 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-04-28

Study results available
· View outcomes & findings →

Summary

Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic hepatitis C (HCV) genotype 1 (GT1) infection

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

CDI-31244

investigational drug

DRUG

SOF/VEL

sofosbuvir and velpatasvir fixed dose combination

Sponsors & Collaborators

  • Cocrystal Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Joel Chua, MD · Institute of Human Virology, University of Maryland, Baltimore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-26
Primary Completion
2019-01-08
Completion
2019-06-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03501550 on ClinicalTrials.gov